Top Line: What is the risk of radiation myelitis after spine SBRT?
The Study: Across multiple studies and series, the reported risk of myelitis is extremely low after spine SBRT that conforms to widely used dose constraints. This retrospective study from MSKCC reviewed outcomes from a large cohort of 1423 patients who received fractionated SBRT to 1904 spine metastases. It included only patients who were treated at levels of the true spinal cord (C1 to L2). The most common prescription dose was 27 Gy in 3 fractions. The PTV was a 2mm expansion of the CTV. In the majority of cases (85%), the spinal cord was delineated using a myelogram performed during the CT simulation. In the other cases, the cord planning structure was a 1mm PRV around the spinal cord delineated on T2 MRI. The institutional planning goals for the cord (or PRV) were Dmax <24 Gy and D0.35cc <18 Gy. However, the latter could be exceeded provided the 18 Gy isodose line did not transect the spinal cord. The rate of radiographic myelitis was 1.6%, and the rate of grade 3-4 myelitis was 1%. The median time to myelitis was 10 months. Interestingly, one patient developed myelitis at two different treatment sites. Of the 30 cases of myelitis, 90% were symptomatic, 22% had reversible symptoms, and 13% had paraplegia. The median spinal cord Dmax was 20.8 Gy, the median D0.03cc was 19.6 Gy, and the median D0.1cc was 18.8 Gy. In 93.3% of myelitis cases, the cord D0.1cc was greater than the median. A dose-response model generated from this data estimated a 1% risk of grade 3-4 myelitis at 2 years when the spinal cord Dmax was limited to 20.8 Gy and the D0.1cc was limited to 19.1 Gy in 3 fractions.
TBL: This large study of 3-fraction spine SBRT found a low risk of myelitis that could be limited to 1% or less when the cord Dmax was limited to 20.8 Gy and the cord D0.1cc was limited to 19.1 Gy. | Jackson, JAMA Oncol 2024
The Study: Across multiple studies and series, the reported risk of myelitis is extremely low after spine SBRT that conforms to widely used dose constraints. This retrospective study from MSKCC reviewed outcomes from a large cohort of 1423 patients who received fractionated SBRT to 1904 spine metastases. It included only patients who were treated at levels of the true spinal cord (C1 to L2). The most common prescription dose was 27 Gy in 3 fractions. The PTV was a 2mm expansion of the CTV. In the majority of cases (85%), the spinal cord was delineated using a myelogram performed during the CT simulation. In the other cases, the cord planning structure was a 1mm PRV around the spinal cord delineated on T2 MRI. The institutional planning goals for the cord (or PRV) were Dmax <24 Gy and D0.35cc <18 Gy. However, the latter could be exceeded provided the 18 Gy isodose line did not transect the spinal cord. The rate of radiographic myelitis was 1.6%, and the rate of grade 3-4 myelitis was 1%. The median time to myelitis was 10 months. Interestingly, one patient developed myelitis at two different treatment sites. Of the 30 cases of myelitis, 90% were symptomatic, 22% had reversible symptoms, and 13% had paraplegia. The median spinal cord Dmax was 20.8 Gy, the median D0.03cc was 19.6 Gy, and the median D0.1cc was 18.8 Gy. In 93.3% of myelitis cases, the cord D0.1cc was greater than the median. A dose-response model generated from this data estimated a 1% risk of grade 3-4 myelitis at 2 years when the spinal cord Dmax was limited to 20.8 Gy and the D0.1cc was limited to 19.1 Gy in 3 fractions.
TBL: This large study of 3-fraction spine SBRT found a low risk of myelitis that could be limited to 1% or less when the cord Dmax was limited to 20.8 Gy and the cord D0.1cc was limited to 19.1 Gy. | Jackson, JAMA Oncol 2024

